You are here: Industry Insights > glioblastoma

News List

BMS blockbuster Opdivo falls short at Phase 3 in MGMT-unmethylated glioblastoma multiforme pharmafile
May 16, 2019
Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) has hit a hurdle, failing its primary endpoint in a Phase 3 trial investigating its efficacy in the treatment of ...
AI uses patient data to administer less toxic treatments europeanpharmaceuticalreview
April 17, 2019
The researchers found that doses were often missed, with some treatments being scheduled twice a year instead of monthly…
New glioblastoma cancer vaccine shows promise in phase 1b clinical trial europeanpharmaceuticalreview
April 02, 2019
A brain-cancer vaccine more than 20 years in the making suspends cancer growth in patients enrolled in early-stage trial…
AIVITA Completes Treatment of First Patient in Phase 2 Ovarian Cancer Trial americanpharmaceuticalreview
February 26, 2019
AIVITA Biomedical announced its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial.....
AI player twoXAR teams up with 1ST Biotherapeutics on glioblastoma fiercebiotech
January 04, 2019
TwoXAR and South Korea’s 1ST Biotherapeutics are joining forces to discover and develop new treatments for glioblastoma, the most aggressive kind of brain cancer.....
Ribociclib could be used to treat glioblastoma europeanpharmaceuticalreview
November 21, 2018
Ribociclib, a drug approved to treat breast cancer, could be used to treat one of the deadliest forms of cancer – glioblastoma…
AIVITA Announces Treatment of First Two Patients in Phase 2 Glioblastoma Trial americanpharmaceuticalreview
November 20, 2018
AIVITA Biomedical has dosed the first two patients in its Phase 2 clinical trial in patients with newly diagnosed gliobl
NICE backs use of dye for brain tumour removal pharmatimes
July 12, 2018
NICE has published new guidelines recommending use of a chemical dye to assist neurosurgeons in removing brain tumours.
Ibrutinib may benefit glioblastoma patients europeanpharmaceuticalreview
June 01, 2018
An FDA-approved drug for lymphoma and leukaemia may also help treat the most common – and deadliest type of brain tumour…
Optune Analysis Finds Predicted Increased Survival in Glioblastoma Patients americanpharmaceuticacreview
November 20, 2017
Novocure announced results from a retrospective post-hoc analysis of its phase 3 pivotal EF-14 trial data showing that increased compliance with Optune predicted increased survival in glioblastoma (GBM) patients.

Previous page 1 2 3 4 Next page